Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06323837 · ClinicalTrials.gov registry record · Phase 2

Mirtazapine for the Treatment of Methamphetamine Use in Opioid Use Disorder Patients Receiving Medication Assisted Treatment

A Phase 2 study of Stimulant Use Disorder, sponsored by Washington State University.

Recruiting
Registry status
Phase 2
Development phase
60
Enrollment target
1
Study location

NCT06323837 is a Phase 2 study of Stimulant Use Disorder that is actively recruiting participants, run by Washington State University. The registered enrollment target is 60 participants, below the 204-participant average among 9 other Stimulant Use Disorder trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06323837, a Phase 2 study of Stimulant Use Disorder, is actively recruiting participants, sponsored by Washington State University.

RECRUITING
Registry status
Phase 2
Development phase
60 participants
Enrollment target
1
Study location

Study Summary

This project will evaluate the ability of Mirtazapine (MZP), a pharmacologically unique medication with a growing body of evidence to support its efficacy and safety for the treatment of methamphetamine (MA) use among medication for opioid use disorder (MOUD) patients, to significantly decrease MA use and related health-impairing behaviors. MZP has already successfully been used in the treatment of methamphetamine (detailed further below and in the Appendices). The investigators hypothesize that those assigned to the MZP plus treatment as usual (TAU) MZP+TAU arm will demonstrate significantly increased rates of biochemically verified abstinence from MA and other substances of abuse and experience improvements in health impairing behaviors relative to the placebo (PLO)+TAU arm across the 10-week treatment and follow-up periods.

Conditions Studied

Stimulant Use Disorder

Interventions

  • DRUG Placebo
  • DRUG Mirtazapine

Study Locations (1)

Washington

  • Spokane Treatment Center - Spokane

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2024-06-17
Est. Completion 2026-09-01
Phase Phase 2

Sponsor

Washington State University

64 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06323837

The ClinicalTrials.gov registry entry for NCT06323837 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 204-participant average among 9 other Stimulant Use Disorder trials with a reported enrollment target (71% lower). The listed sponsor is Washington State University, which has 64 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Stimulant Use Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06323837 reports 1 study location spanning 1 distinct geographic area - top geographies include Washington.

Frequently Asked Questions

What is clinical trial NCT06323837 about?

NCT06323837 is a clinical study titled "Mirtazapine for the Treatment of Methamphetamine Use in Opioid Use Disorder Patients Receiving Medication Assisted Treatment". This project will evaluate the ability of Mirtazapine (MZP), a pharmacologically unique medication with a growing body of evidence to support its efficacy and safety for the treatment of methamphetamine (MA) use among medication for opioid use disorder (MOUD) patients, to significantly decrease MA u...

What is the current status of trial NCT06323837?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2024-06-17. Estimated completion is 2026-09-01.

What conditions does trial NCT06323837 study?

This clinical trial studies the following conditions: Stimulant Use Disorder.

What interventions are being tested in trial NCT06323837?

The interventions under investigation include: Placebo (DRUG), Mirtazapine (DRUG).

Who is sponsoring clinical trial NCT06323837?

This trial is sponsored by Washington State University, which has 64 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06323837 being conducted?

This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Stimulant Use Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Stimulant Use Disorder

All registered trials for this condition

Washington

All trials with a study site in Washington

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.